API

Dicyclomine (10mg) + Mefenamic Acid (250mg)

Drug classification

Antispasmodic (Dicyclomine) and nonsteroidal anti-inflammatory drug—NSAID (Mefenamic Acid).

Dosage form

Film-coated oral tablet containing dicyclomine 10mg and mefenamic acid 250mg.

API strength per dosage

Dose

Meftal-Spas Tablet is typically taken 1 tablet two to three times daily after meals in adults. Use in children is not well established; consult a physician. Caution is advised in renal or hepatic impairment—dose adjustment or avoidance may be necessary. Prolonged use or high doses increase risk of adverse effects; use the lowest effective dose.

Mechanism of action

Dicyclomine is a competitive antagonist at muscarinic acetylcholine receptors (mainly M3) in smooth muscle, reducing gastrointestinal motility and spasm. Mefenamic acid inhibits cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, which reduces inflammation and pain. Together, they relieve abdominal pain and cramps.

Indications

Treatment of Menstrual painTreatment of Abdominal cramp

Side effects

Dizziness Dryness in mouth Blurred vision Nausea Sleepiness Weakness Nervousness

Pregnancy category

Meftal-Spas contains dicyclomine and mefenamic acid; both should generally be avoided in pregnancy unless clearly needed, especially during the third trimester. Consult a physician.

Precautions

Avoid in patients with GI obstruction, urinary retention, glaucoma, severe renal/hepatic impairment, history of peptic ulcer or GI bleeding, asthma, elderly, pregnancy, lactation; monitor for anticholinergic effects, GI symptoms, renal/hepatic function, allergic reactions, blood counts, and signs of CNS effects.

Contraindications

Hypersensitivity to dicyclomine, mefenamic acid, or NSAIDs, active peptic ulcer, GI bleeding, obstructive uropathy, paralytic ileus, severe ulcerative colitis, myasthenia gravis, severe renal or hepatic impairment, infants under 6 months.